HSRC REPORT: This paper considers the short and longer term options for aligning supply and demand of artemisin-based combination therapy (ACT) for Malaria. This is set on a background of increasing pressure for countries to change their anti-malaria drug policy to ACT (Artemisin-based Combination Therapies), by the World Health Organisation. However, despite the fact that many countries have changed their drug policies, this has not translated into firm demands for ACTs from manufacturers. The result is that there is no incentive for manufacturers to increase supply of ACTs, leading to discrepancies between supply and demand of ACTs. This paper attempts to explore the causes for these discrepancies, their implications and proffer recommendations to addressing these issues.